COMMUNIQUÉS West-GlobeNewswire

-
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
31/01/2024 -
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
31/01/2024 -
Nanobiotix participera à la 6ème conférence annuelle de Biotechnologie de Guggenheim
31/01/2024 -
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/01/2024 -
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
31/01/2024 -
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
31/01/2024 -
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
31/01/2024 -
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
31/01/2024 -
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
31/01/2024 -
Compass Pathways to participate in upcoming Oppenheimer investor conference
31/01/2024 -
AHG Announces Plan to Acquire Online Clinic
31/01/2024 -
Merus annonce la tenue d’une série de conférences auprès des investisseurs
31/01/2024 -
SAFE - Lettre aux actionnaires
31/01/2024 -
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
31/01/2024 -
BioSig Announces Reverse Stock Split
31/01/2024 -
Total number of shares and voting rights in Zealand Pharma at January 31, 2024
31/01/2024 -
BBS-Bioactive Bone Substitutes Plc has resolved on a share issue without consideration to the company itself
31/01/2024 -
PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
31/01/2024 -
Coloplast launches Biatain® Silicone Fit for pressure injury prevention and wound management in the US
31/01/2024
Pages